– Marc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors –

－马克·福思辞去总裁兼首席执行官职务，寻求另一机会；将继续留任董事会成员－

– Jost Fischer, Chairman of AEON, will assume the role of interim CEO –

－AEON董事长乔斯特·费舍尔将担任临时首席执行官－

IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today a leadership transition under which Marc Forth is stepping down as President and Chief Executive Officer of the Company to pursue another opportunity, effective April 4, 2025.

加利福尼亚州欧文市，2025年3月27日（环球新闻社）——AEON生物制药公司（“AEON”或“公司”）（纽约证券交易所代码：AEON），一家专注于开发肉毒杆菌毒素复合物用于治疗多种适应症的临床阶段生物制药公司，今天宣布了一项领导层过渡，Marc Forth将辞去公司总裁兼首席执行官的职务，以追求另一机会，自2025年4月4日起生效。

Mr. Forth will continue with the Company as a member of its board of directors (the “Board”), through which he will continue to advise the Company’s management team and provide strategic guidance. The Board has appointed Jost Fischer, the current Chairman of the Board, to serve as Interim Chief Executive Officer following Mr.

福思先生将继续作为董事会成员留在公司，通过这一职位他将继续为公司的管理团队提供咨询并给予战略指导。董事会已任命现任董事会主席约斯特·费舍尔在福思先生之后担任临时首席执行官。

Forth’s departure while the Board identifies a replacement chief executive officer. The Board is actively considering several qualified candidates..

在董事会确定替代首席执行官之前，福思将离职。董事会正在积极考虑几位合格的候选人。

“On behalf of the Board, I want to thank Marc for his invaluable contributions to AEON over the last several years and his dedication to exhaustively evaluating all opportunities for the Company to execute its growth strategy. As a result of these efforts, the Company is making steady progress along a 351(k) biosimilar regulatory pathway that could allow it to bring ABP-450 to the U.S.

“代表董事会，我要感谢马克在过去几年中为AEON做出的宝贵贡献，以及他致力于全面评估公司执行增长战略的所有机会。通过这些努力，公司正在稳步推进沿351(k)生物类似药监管路径的进展，这可能使其能够将ABP-450引入美国市场。

market for all of BOTOX’s currently approved and future therapeutic indications under a single FDA approval,” commented Mr. Fischer.  “I look forward to working with the AEON team and the Board to ensure our program for ABP-450 continues to move forward without delay. We believe our current cash balance will allow us to work through our Biosimilar BPD Type 2a meeting with FDA anticipated in the second half of 2025.

“BOTOX所有已获批和未来治疗适应症的市场将归于单一FDA批准之下，”费舍尔先生评论道。“我期待与AEON团队和董事会合作，确保我们ABP-450项目继续毫无延误地推进。我们相信，我们目前的现金余额将足以支持我们在2025年下半年预期与FDA举行的生物类似药BPD 2a型会议。”

We look forward to announcing the results of that meeting and next steps in our development program.”.

我们期待着宣布该会议的结果以及我们开发计划的下一步。”

Jost Fischer has served as a member of the Company’s Board since February 2017. Mr. Fischer is the co-owner of Dental Innovations BVBA. Mr. Fischer served as a member and the chairman of the board of directors and as Chief Executive Officer of Sirona from June 2006 to February 2013, as Chief Executive Officer from April 2002 to February 2013, and as President from April 2002 to September 2010.

自2017年2月起，乔斯特·菲舍尔一直担任公司董事会成员。菲舍尔先生是Dental Innovations BVBA的共同所有人。2006年6月至2013年2月，菲舍尔先生曾担任西诺德（Sirona）董事会成员及主席，并于2002年4月至2013年2月担任首席执行官，以及2002年4月至2010年9月担任总裁。

Prior to joining Sirona, Mr. Fischer served as President and Chief Executive Officer of The Hoermann Group, an international conglomerate in the telecommunication and automotive industry, and held senior management positions with PWA Group, a European paper group, including President and Chief Executive Officer of PWA’s printing division and President and Chief Executive Officer of PWA Dekor GmbH.

在加入西诺德之前，费舍尔先生曾担任电信和汽车行业国际集团霍曼集团的总裁兼首席执行官，并在欧洲纸业集团PWA集团担任过多个高级管理职位，包括PWA印刷部门的总裁兼首席执行官以及PWA装饰有限公司的总裁兼首席执行官。

In addition, Mr. Fischer serves on the board of directors of several private companies. He received a Master’s degree in Economics from the University of Saarbruecken, Germany..

此外，费舍尔先生还在几家私人公司的董事会任职。他获得了德国萨尔布吕肯大学的经济学硕士学位。

About AEON Biopharma

关于AEON生物制药公司

AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau.

AEON是一家临床阶段的生物制药公司，专注于开发其专有的肉毒杆菌毒素复合物ABP-450（prabotulinumtoxinA）注射剂，或称ABP-450，用于治疗使人衰弱的医疗状况，最初的重点是神经科学市场。ABP-450与目前由Evolus以Jeuveau名称获批并上市用于美容适应症的肉毒杆菌毒素复合物相同。

ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories.

ABP-450由大熊制药公司按照现行良好生产规范（cGMP）生产，其生产设施已获得美国食品药品监督管理局、加拿大卫生部和欧洲药品管理局的批准。该产品在墨西哥和印度被批准为生物类似药。AEON公司拥有ABP-450在美国、加拿大、欧盟、英国及某些其他国际地区的治疗适应症的独家开发和分销权。

The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit .

公司组建了一支经验丰富的管理团队，该团队在生物制药和肉毒杆菌毒素的开发及商业化方面具有特定的专业知识。如需了解更多关于AEON的信息，请访问。

www.aeonbiopharma.com

www.aeonbiopharma.com

.

。

Forward-Looking Statements

前瞻性声明

Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or AEON’s future financial or operating performance. For example, statements regarding meetings with the FDA, the timing of primary comparative analytical studies, and potential determination that ABP-450 is highly similar to the reference product for currently approved and future therapeutic indications are forward-looking statements.

本新闻稿中的某些声明可能被视为前瞻性声明。前瞻性声明通常与未来事件或永旺公司未来的财务或运营表现有关。例如，关于与FDA会面、主要对比分析研究的时间安排，以及可能认定ABP-450与目前获批及未来治疗适应症的参比产品高度相似的声明均为前瞻性声明。

In some cases, you can identify forward-looking statements by terminology such as 'plan', 'possible', 'forecast', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential', 'continue' or 'could', or the negatives of these terms or variations of them or similar terminology.

在某些情况下，您可以通过诸如“计划”、“可能”、“预测”、“预期”、“打算”、“将”、“估计”、“预计”、“相信”、“推测”、“潜在”、“继续”或“可能”等术语，或这些术语的否定形式、变体或类似表述来识别前瞻性陈述。

Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements..

此类前瞻性陈述受风险、不确定性和其他因素的影响，这些因素可能导致实际结果与这些前瞻性陈述所表达或暗示的结果有重大差异。

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by AEON and its management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the outcome of any legal proceedings that may be instituted against AEON or others; (ii) AEON’s future capital requirements; (iii) AEON’s ability to raise financing in the future; (iv) AEON’s ability to maintain the cash balance required to work through our Biosimilar BPD Type 2a meeting with the FDA; (v) AEON’s ability to continue to meet continued stock exchange listing standards; (vi) the possibility that AEON may be adversely affected by other economic, business, regulatory, and/or competitive factors; (vii) AEON’s ability to progress along a 351(k) biosimiliar pathway to allow ABP-450 to be approved as a biosimilar to BOTOX under a single FDA approval; (viii) the outcomes from any meetings or discussions with regulatory authorities; and (ix) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the Securities and Exchange Commission (the 'SEC'), which are available on the SEC’s website at .

这些前瞻性陈述基于AEON及其管理层认为合理的估计和假设，但本质上仍存在不确定性。可能导致实际结果与当前预期产生重大差异的因素包括但不限于：(i) 可能对AEON或其他方提起的任何法律诉讼的结果；(ii) AEON未来的资本需求；(iii) AEON未来筹集资金的能力；(iv) AEON维持足够现金余额以应对与FDA召开的Biosimilar BPD 2a类型会议的能力；(v) AEON继续满足持续的证券交易所上市标准的能力；(vi) AEON可能受到其他经济、商业、监管和/或竞争因素的不利影响的可能性；(vii) AEON沿着351(k)生物类似药路径推进并使ABP-450作为BOTOX的生物类似药获得单一FDA批准的能力；(viii) 与监管机构进行的任何会议或讨论的结果；以及(ix) 公司向证券交易委员会（SEC）提交的文件中“风险因素”和“关于前瞻性陈述的警示说明”部分所述的其他风险和不确定性，这些文件可在SEC的网站上查阅。

www.sec.gov

www.sec.gov

.

。

Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.

本新闻稿中的任何内容均不应被视为任何人对本文所述的前瞻性陈述将会实现或此类前瞻性陈述的任何预期结果将会实现的表示。您不应过分依赖前瞻性陈述，因为这些陈述仅在其发布之日有效。

AEON does not undertake any duty to update these forward-looking statements..

永旺不承担更新这些前瞻性陈述的任何责任。

Contacts

联系人

Investor Contact:

投资者联系方式：

Corey Davis, Ph.D.

科里·戴维斯，博士

LifeSci Advisors

生命科学顾问

+1 212 915 2577

+1 212 915 2577

cdavis@lifesciadvisors.com

cdavis@lifesciadvisors.com

Source: AEON Biopharma

来源：AEON生物制药